glp 1 drugs and pregnancy GLP-1 Receptor Agonists, Fertility Restoration, Reproductive Safety in Women of Reproductive Age: A Narrative Review GLP-1 agonists' safety during pregnancy

Increased FFA in the liver results in insulin resistance, hepatic glucose production, and pancreatic beta cell dysfunction [7]

No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: a pooled analysis of cardiovascular outcome trials

Mark Kennedy has received honoraria for serving as a speaker for and advisory board member of Eli Lilly

There is need for long-term prospective trials of GLP-1 drugs to confirm efficacy in breast cancer prevention

Popularity spiked dramatically following Wegovy's approval, with prescriptions doubling in 2022 and again in 2023

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: BioMedWire Austin, Texas www.BioMedWire.com 512.354.7000 Office [email protected] BioMedWire is powered by IBN